TrialJournal of inherited metabolic disease2025

A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.

Myrl Holida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.